Table 3 Relationship between MRI-detected extramural venous invasion and patient outcome
Author | Year | No. of patients | Neoadjuvant therapy | Endpoint | Hazard ratio (95% CI) |
|---|---|---|---|---|---|
EMVI before neoadjuvant therapy | |||||
Chand [54] | 2014 | 478 | CRT (69.2%: 331/478) | DSF (3 year) | 2.08 (1.10–3.07) |
Sclafani [53] | 2014 | 269 | CRT | PFS (5 year) | 1.85 (1.12–3.05) |
Jalil [59] | 2016 | 56 | CRT | OS | 2.90 (1.00–8.37) |
Patel [55] | 2017 | 46 | Chemotherapy | DSF (3 year) | 31.33 (2.31–425.4) |
Lee [29] | 2018 | 200 | CRT | DSF (3 year) | 1.35 (0.64–2.82) |
OS | 1.18 (0.51–2.77) | ||||
Jia [52] | 2018 | 185 | No | DSF (3 year) | 2.46 (1.28–4.74) |
Meng [56] | 2019 | 115 | CRT | DSF (3 year) | 2.50 (1.24–5.01) |
Gu [57] | 2019 | 146 | short course CRT | DSF (3 year) | 3.56 (2.03–13.32) |
Meng [58] | 2019 | 171 | CRT | DSF (3 year) | 2.59 (1.40–4.80) |
EMVI after neoadjuvant therapy | |||||
Chand [25] | 2015 | 188 | CRT | DSF (3 year) | 1.97 (1.01–3.90) |
Jalil [59] | 2016 | 56 | CRT | OS | 4.23 (1.41–12.69) |
Lee [29] | 2018 | 200 | CRT | DSF (3 year) | 2.68 (1.37–5.27) |
OS | 1.98 (0.88–4.42) | ||||
Shiraishi [60] | 2019 | 102 | Chemotherapy | RFS (5 year) | 2.74 (1.36–5.50) |
OS | 3.15 (0.91–10.89) | ||||